Product data sheet

MedKoo Cat#: 464622 Name: PDD4091 CAS#: 1373651-41-2 Chemical Formula: $C_{19}H_{32}N_2O_3S$ Exact Mass: 368.2134 Molecular Weight: 368.54	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.
	In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:
PDD4091 is a novel G6PD inhibitor.

2. CoA, QC data, SDS, and handling instruction
SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
To be determined	To be determined	To be determined

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.71 mL	13.57 mL	27.13 mL
5 mM	0.54 mL	2.71 mL	5.43 mL
10 mM	0.27 mL	1.36 mL	2.71 mL
50 mM	0.05 mL	0.27 mL	0.54 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator
Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study
In vitro study

To be determined

In vivo study

1. Atsushi Kitagawa, Christina Jacob, Allan Jordan, Ian Waddell, Ivan F. McMurtry and Sachin A. Gupte. Journal of Pharmacology and Experimental Therapeutics May 1, 2021, 377 (2) 284-292; DOI: https://doi.org/10.1124/jpet.120.000166

7. Bioactivity
Biological target:

PDD4091 had a reasonably wide therapeutic window (0.01–15 mg kg-1 day-1) with an EC50 of 0.26 +/- 0.10, and 0.58 +/-0.36 mg kg-1 day-1 reduced both RVSP and RVEDP.

In vitro activity

To be determined

In vivo activity

PDD4091 dose-dependently relaxed PA precontracted with KCl. PDD4091 arrested maladaptive gene expression in vascular cells of the PA wall, reduced cell growth in occlusive pulmonary arterial disease, and dose-dependently relaxed precontracted PAs.

Product data sheet

Reference: J Pharmacol Exp Ther. May 1, 2021, 377 (2) 284-292 https://jpet.aspetjournals.org/content/377/2/284

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.